Barriers to optimizing inflammatory bowel disease care in the United States

被引：7

作者：

Spencer, Elizabeth A. ^{[2
]}

Abbasi, Sadeea ^{[3
]}

Kayal, Maia ^{[1
]}

机构：

[1] Icahn Sch Med Mt Sinai, Henry D Janowitz Div Gastroenterol, One Gustave L Levy Pl Box 1069, New York, NY 10029 USA

[2] Icahn Sch Med Mt Sinai, Div Pediat Gastroenterol, New York, NY USA

[3] Cedars Sinai Santa Monica Gastroenterol, Div Gastroenterol, Santa Monica, CA USA

来源：

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2023年 / 16卷

基金：

美国国家卫生研究院;

关键词：

barriers; inflammatory bowel disease; insurance; HEALTH-CARE; MANAGEMENT; GUIDELINE; THERAPY;

D O I：

10.1177/17562848231169652

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Significant progress in the management and modification of inflammatory bowel disease (IBD) has been made; however, significant barriers to the optimization of IBD care in the United States still exist. The majority of these barriers are constructed by insurance carriers and the integration of market pressures into healthcare decision-making. In this review, we highlight the barriers to IBD care optimization within the context of the US insurance system and review current and proposed solutions.

引用

页数：14

共 50 条

[31] PATIENT, PARENT, AND PROVIDER PERCEPTIONS OF BARRIERS TO PEDIATRIC INFLAMMATORY BOWEL DISEASE CARE
Dotson, Jennifer L.
Bricker, Josh B.
Crandall, Wallace V.
Chisolm, Deena J.
Mackner, Laura M.
GASTROENTEROLOGY, 2018, 154 (01) : S80 - S80
[32] Influence of nonalcoholic fatty liver disease on inflammatory bowel disease hospitalizations in the United States
Soni, Aakriti
Yekula, Anuroop
Dahiya, Dushyant Singh
Sundararajan, Ramaswamy
Dutta, Priyata
Singh, Yuvaraj
Cheng, Chin-, I
Abraham, George
ANNALS OF GASTROENTEROLOGY, 2023, 36 (06): : 646 - +
[33] Utilization of health care resources by individuals with inflammatory bowel disease in the United States: A profile of time since diagnosis
Longobardi, T
Jacobs, P
Bernstein, CN
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2004, 99 (04): : 650 - 655
[34] Optimizing Thiopurine Therapy in Inflammatory Bowel Disease
Chevaux, Jean-Baptiste
Peyrin-Biroulet, Laurent
Sparrow, Miles P.
INFLAMMATORY BOWEL DISEASES, 2011, 17 (06) : 1428 - 1435
[35] Optimizing the use of thiopurines in inflammatory bowel disease
Goel, Rishi M.
Blaker, Paul
Mentzer, Alex
Fong, Steven C. M.
Marinaki, Anthony M.
Sanderson, Jeremy D.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2015, 6 (03) : 138 - 146
[36] Optimizing pharmacologic management of inflammatory bowel disease
Chang, Shannon
Hanauer, Stephen
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (06) : 595 - 607
[37] Optimizing drug therapy in inflammatory bowel disease
Swaminath A.
Kornbluth A.
Current Gastroenterology Reports, 2007, 9 (6) : 513 - 520
[38] Optimizing conventional therapies for inflammatory bowel disease
Sparrow M.P.
Irving P.M.
Hanauer S.B.
Current Gastroenterology Reports, 2009, 11 (6) : 496 - 503
[39] Optimizing immunomodulator therapy for inflammatory bowel disease
Marla C. Dubinsky
Current Gastroenterology Reports, 2003, 5 (6) : 506 - 511
[40] Optimizing conventional therapy for inflammatory bowel disease
Schwartz M.
Cohen R.
Current Gastroenterology Reports, 2008, 10 (6) : 585 - 590

← 1 2 3 4 5 →